Advertisement
New Zealand markets closed

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NZD/USD

    0.5888
    -0.0017 (-0.29%)
     

  • NZD/EUR

    0.5530
    -0.0015 (-0.26%)
     

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • OIL

    83.69
    +0.96 (+1.16%)
     

  • GOLD

    2,396.60
    -1.40 (-0.06%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,837.40
    +67.38 (+0.38%)
     

  • Hang Seng

    16,224.32
    -161.55 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • NZD/JPY

    90.8980
    -0.3560 (-0.39%)
     

Elagolix May Advance the Treatment Paradigm in Women’s Health

Margaret Patrick
Updated
Elagolix May Advance the Treatment Paradigm in Women’s Health

On October 27, 2017, AbbVie (ABBV) announced that the New Drug Application (or NDA) for its investigational drug Elagolix, which is used for managing endometriosis-related pain, had been granted priority review by the FDA. AbbVie has developed Elagolix in collaboration with Neurocrine Biosciences (NBIX). AbbVie expects this oral gonadotropin-releasing hormone (or GnRH) antagonist to be approved by its Prescription Drug User Fee Act (or PDUFA) date in 2Q18.

Continue reading